Data on 3,363 overweight and obese patients revealed that those who took a combination of naltrexone and bupropion for a year attained a 0.17% reduction in the predicted 10-year risk of cardiovascular events, compared with a 0.05% reduction in those who had a placebo treatment. Researchers found no significant impact on the predicted risk of ischemic heart disease, cardiovascular mortality or stroke in patients. The findings were presented at the Obesity Society meeting.

Related Summaries